Christian Schade
Executive Chair
Chris is a Senior Advisor on the Frazier Life Sciences team.
Chris joined the Frazier Life Sciences team in 2026 with over 30 years of experience across private and public biopharma companies as a seasoned executive.
Prior to joining Frazier Life Sciences, Chris was the President and Chief Executive Officer of Halda Therapeutics, a company developing a novel class of cancer therapies, until its $3.050 billion sale to Johnson & Johnson in December 2025. Prior to Halda, Chris was a Growth Partner at Flagship Pioneering.
Chris was President and Chief Executive Officer and Board member of Aprea Therapeutics (Nasdaq: APRE) from 2016 to 2022, including as Chairman from 2020 to 2023. He led Aprea in developing its pipeline of anti-cancer therapies through the company’s IPO in 2019. Chris has also served in executive leadership positions at several other biotech companies with emerging clinical candidates including: Chief Executive Officer of Novira, a privately held antiviral drug discovery company until it was acquired by Johnson & Johnson; Chief Financial Officer of Omthera Pharmaceuticals, Inc., a Nasdaq-listed specialty pharmaceuticals company focused on new therapies for dyslipidemia until it was acquired by AstraZeneca Plc; and, Senior Vice President of Administration and Chief Financial Officer at Medarex, Inc, a biopharmaceutical company focused on antibody-based therapeutic products for oncology, inflammation, autoimmune disorders, and infectious diseases until it was acquired by Bristol-Myers Squibb.